Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy.
We describe a patient with sight threatening thyroid associated ophthalmopathy (TAO) who was successfully treated with infliximab, an anti-tumour necrosis factor (TNF)-a antibody.
Durrani
O M
OM
Academic Unit of Ophthalmology, the University of Birmingham, UK.
Reuser
T Q
TQ
Murray
P I
PI
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005128:Eye Diseases / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006111:Graves Disease / Q000150:complications*; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab